Work

A cost-effectiveness analysis of the AURELIA trial: Bevacizumab and paclitaxel offer a promising clinical and economic combination for platinum-resistant ovarian cancer

Year: 2016

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2016.04.117

Authors: J.L. Lesnock, C.A. Hamilton, K.M. Darcy, L.J. Havrilesky, T.C. Krivak, G.L. Maxwell, W.J. Lowery

Institutions: Walter Reed National Military Medical Center, Duke Medical Center, Western Pennsylvania Hospital, Inova Fairfax Hospital

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2467294904

FWCI:

Cites:

Cited by: 1

Related to: 10